Quarter
Charts

Artiva Biotherapeutics, Inc. — Key Metrics

1 years of history · ending 2024-12-31 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Expense Ratios

Working Capital Analysis

Valuation Multiples

Enterprise Value Multiples

52-Week Range

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-6
Book Value Per Share
$17
Free Cash Flow Per Share
$-5
Cash Per Share
$4
Revenue Per Share
$0
OCF Per Share
$-5
Return on Equity
-530.9%
Return on Assets
-41.5%
Return on Invested Capital
-546.4%
Current Ratio
15.39
Quick Ratio
15.39
Asset Turnover
0.00
Days Sales Outstanding
0.00
R&D / Revenue
20051.0%
SBC / Revenue
2780.9%
Capex / Revenue
255.8%
Working Capital
$176M
Net Current Asset Value
$166M
Invested Capital
$187M
OCF / Net Income
0.84
FCF / Net Income
0.85
Accruals Ratio (Sloan)
-4.9%
Net Debt
$-185M
Net Debt / EBITDA
2.86
Capex Coverage
-85.72
Tangible Common Equity
$187M
TCE / Total Assets
89.1%
NOPAT
$-67M
Cash ROIC
-452.2%
WC / Revenue
70270.1%
Capex / D&A
0.26
Reinvestment Rate
2.7%
Asset Growth vs Revenue Growth
198.6%
Stock Price (FY-end)
$10
Market Cap
$113M
P/S Ratio
452.15
P/B Ratio
0.61
P/TB Ratio
0.61
Enterprise Value
$-72M
EV / Sales
-286.61
FCF Yield
-49.1%
Shareholder Yield
-6.2%
R&D Yield
44.3%
Capex Yield
0.6%
Shares Variation (YoY)
1302.5%
Beta (5Y)
1.45
Cost of Equity
11.8%
52W High
$16
52W Low
$10
Trailing Return 1Y
—
F-Score (Piotroski)
2.00
Z-Score (Altman)
1.27

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Stock Price on Earnings Dates

Artiva Biotherapeutics, Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2024FY2025
Federal Statutory Rate21.00%21.00%
State & Local Income Taxes0.38%0.35%
Foreign Rate Differential——
Other Adjustments-0.11%-0.01%
R&D Tax Credits4.00%3.84%
SBC (Nondeductible)1.55%-1.43%
Valuation Allowance Change-21.77%-21.94%
Effective Tax Rate0.00%0.00%

Cash vs Accrual

ItemFY2024FY2025
Income Tax Expense (Accrual)——
Income Taxes Paid (Cash)——